Dergiler / Dicle Tıp Dergisi / 2023 / Cilt 50, Sayı 3

The Role of Steroid Receptors in the Proliferation and Migration of Endometrial Adenocarcinoma HEC1A Cell Line

Sayfa
327–334
Yayın Tarihi
2023-09-15
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: These results suggest that, unlike other steroid receptors, glucocorticoid and/or progesterone receptors may play an important role in the reducing migration of endometrial carcinoma and might be used as targets to reduce the metastasis of this type of cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Endometrial carcinoma is one of the most common gynecological cancers.
📊
Temel Bulgular & Veri:Thus in this study, we aimed to examine the role of compounds acting on steroid receptors in type II, on HEC1A cultured cells.
💡
Sonuç & Katkı:Conclusions: These results suggest that, unlike other steroid receptors, glucocorticoid and/or progesterone receptors may play an important role in the reducing migration of endometrial carcinoma and might be used as targets to reduce the metastasis of this type of cancer.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Endometrial adenocarcinoma · steroid receptors · proliferation

Abstract

Objectives: Endometrial carcinoma is one of the most common gynecological cancers. It is generally divided into oestrogen-dependent type I, and oestrogen-independent type II. Although the expression of some steroid receptors has been documented in type II endometrial carcinoma, their roles in tumor progression have not been fully elucidated yet. Thus in this study, we aimed to examine the role of compounds acting on steroid receptors in type II, on HEC1A cultured cells. Methods: We tested the effect of mifepristone (the glucocorticoid and progesterone receptor blocker, 10-8M), bicalutamide (the androgen receptor blocker, 10-6M), G15 (the G-protein-coupled estrogen receptor-1 blocker, 10-7M) and PHTPP (2-Phenyl-3-(4-hydroxyphenyl)-5,7-bis (trifluoromethyl)-pyrazolo [1,5-a]pyrimidine, the estrogen receptor-β blocker, 10-7M), on proliferation. Proliferation was assessed by xCELLigence analysis system and migration was examined by using wound-healing model. Results: None of the drugs, at the used concentrations, have affected the proliferation of HEC1A cells. However, migration was significantly increased at the 24th and the 48th hour of mifepristone application (p<0.05, P<0.01, respectively). Bicalutamide also increased migration at the 24th hour (p<0.05). G15 and PHTPP did not change the migration of cells. Conclusions: These results suggest that, unlike other steroid receptors, glucocorticoid and/or progesterone receptors may play an important role in the reducing migration of endometrial carcinoma and might be used as targets to reduce the metastasis of this type of cancer.

🔖

Bu Makaleye Atıf Yap

HENNAWİ, K. A., TİFTİK, R. N., ÜN, İ., BÜYÜKAFŞAR, K. (2023). The Role of Steroid Receptors in the Proliferation and Migration of Endometrial Adenocarcinoma HEC1A Cell Line. Dicle Tıp Dergisi, Cilt 50, Sayı 3, 327–334. https://ajindex.com/articles/962716

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents, Vol. XI. Lyon: IARC Publication;2018. 2.https://gco.iarc.fr/today/home. Source: Globocan 2020 (Turkey) Accessed April 19, 2023. 3.Felix AS, Weissfeld JL, Stone RA, et al. Factorsassociated with Type I and Type II endometrialcancer. Cancer Causes Control. 2010;1(11):1851-6. 4.Setiawan VW, Yang HP, Pike MC, et al. Type I andII Endometrial Cancers: Have They Different RiskFactors? J Clin Oncol. 2013;31(20):2607-18. 5.Gronemeyer H, Gustafsson JÅ, Laudet V. Principles for modulation of the nuclear receptor superfamily.Nat Rev Drug Discov. 2004;3(11):950-64. 6.Ahmad N, Kumar R. Steroid hormone receptors incancer development: A target for cancertherapeutics. Cancer Lett. 2011;1:300(1):1-9. 7.Shen F, Gao Y, Ding J, Chen Q. Is the positivity ofestrogen receptor or progesterone receptordifferent between type 1 and type 2 endometrialcancer? Oncotarget. 2017;3;8(1):506-11. 8.Zhang Y, Guo R, Ge X, Qiao Y. Effect of GPER on theactivation of PI3K/Akt induced by 17β-estradiol inendometrial carcinoma cells Zhonghua Fu Chan KeZa Zhi. 2012;47(4):292-6. 9.Hashimoto C, Miki Y, Tanaka S, et al. 17β-hydroxysteroid dehydrogenase type 2 expression isinduced by androgen signaling in endometrialcancer. Int J Mol Sci. 2018;10;19(4):1139. 10.Circirci Y, Tiftik RN, Un İ. Effect of the Wnt/β-catenin pathway inhibitors on cell proliferation andmig ration of HEC-1A endometrial adenocarcinoma:experimental cell culture model. Eur Res J.2021;7(3):218-24. 11.Li A, Felix JC, Minoo P, Amezcua CA, Jain JK. Effectof mifepristone on proliferation and apoptosis ofIshikawa endometrial adenocarcinoma cells. FertilSteril. 2005;84(1):202-11. 12.Sang L, Lu D, Zhang J, Du S, Zhao X. Mifepristoneinhibits proliferation, migration and invasion ofHUUA cells and promotes its apoptosis by regulation of FAK and PI3K/AKT signaling pathway. OncoTargets Ther. 2018;4:11:5441-49. 13.Ponikwicka-Tyszko D, Chrusciel M,Stelmaszewska J, et al. Molecular mechanismsunderlying mifepristone’s agonistic action onovarian cancer progression. EBioMedicine.2019;1:47:170-83. 14.Parker C, Castro E, Fizazi K, et al. Prostate cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up†. Ann Oncol.2020;31(9):1119-1134. 15.Li J, Xiang S, Zhang Q, et al. Combination ofcurcumin and bicalutamide enhanced the growthinhibition of androgen-independent prostate cancercells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp